The approval was supported by pooled data from 2 open-label, single arm trials: the phase 2 NI-0501-06 study and the phase 3 EMERALD trial.

Stockholm, Sweden Monday, June 30, 2025, 10:00 Hrs [IST] ...

The drug has been authorised to treat adult and paediatric patients with haemophagocytic lymphohistiocytosis (HLH)/MAS in known or suspected Still’s disease, including systemic juvenile idiopathic ...